41 related articles for article (PubMed ID: 9170954)
21. A chink in HIV's armour?
Stephens PE; Clements G; Yarranton GT; Moore J
Nature; 1990 Jan; 343(6255):219. PubMed ID: 2300166
[No Abstract] [Full Text] [Related]
22. Key statistician ousted as Waxman enters gp160 fray.
Macilwain C
Nature; 1993 Jul; 364(6436):374. PubMed ID: 8332203
[No Abstract] [Full Text] [Related]
23. A sensitive mapping strategy for monitoring the reproducibility of glycan processing in an HIV vaccine, RGP-160, expressed in a mammalian cell line.
Tran NT; Taverna M; Merry AH; Chevalier M; Morgant G; Valentin C; Ferrier D
Glycoconj J; 2000 Jun; 17(6):401-6. PubMed ID: 11294506
[TBL] [Abstract][Full Text] [Related]
24. Which gp160 vaccine?
Moore J; Lewis GK; Robinson J
Nature; 1993 Feb; 361(6412):503. PubMed ID: 7679205
[No Abstract] [Full Text] [Related]
25. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
Saphire EO; Parren PW; Pantophlet R; Zwick MB; Morris GM; Rudd PM; Dwek RA; Stanfield RL; Burton DR; Wilson IA
Science; 2001 Aug; 293(5532):1155-9. PubMed ID: 11498595
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1.
Meyuhas R; Noy H; Montefiori DC; Denisova G; Gershoni JM; Gross G
Mol Immunol; 2005 May; 42(9):1099-109. PubMed ID: 15829299
[TBL] [Abstract][Full Text] [Related]
27. The antigenic structure of the HIV gp120 envelope glycoprotein.
Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
[TBL] [Abstract][Full Text] [Related]
28. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
29. Prime-boost immunization strategies against HIV.
Barnett SW; Klinger JM; Doe B; Walker CM; Hansen L; Duliège AM; Sinangil FM
AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S299-309. PubMed ID: 9814958
[No Abstract] [Full Text] [Related]
30. [Possible use of recombinant CD4 in the therapy of AIDS].
Praglia C
Minerva Pediatr; 1990; 42(1-2):49-51. PubMed ID: 2110615
[No Abstract] [Full Text] [Related]
31. [Analysis of the principal neutralization site of HIV-1 and vaccine research].
Okamoto Y; Honda M
Tanpakushitsu Kakusan Koso; 1997 May; 42(7 Suppl):1201-8. PubMed ID: 9170954
[No Abstract] [Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]